Rivaroxaban in patients with abdominal aortic aneurysm and high-sensitivity C-reactive protein elevation (BANBOO): study protocol for a randomized, controlled trial

Table 1 Collecting information on visits

Follow-up	Baseline (visit 1)	1 month (visit 2, ± 7 days)	6 months (visit 3, ± 7 days)
Inclusion/exclusion criteria	X
Physical examination	X
Vital signs	X
ICF	X
Contact information	X
Demographic data	X
Previous history	X
Admitting diagnosis	X
Subject guidance	X
Drug therapy	X	X	X
hs-CRP	X	X	X
Imaging examination	X		X
MACCE		X	X
Other laboratory tests	X	X	X
Bleeding events (BARC)	X	X	X
Liver function	X	X	X
Renal function	X	X	X
Subject compliance		X	X

ICF inform consent form, hs-CRP high-sensitivity C-reactive protein, MACCE major adverse cardiovascular and cerebrovascular event, BARC Bleeding Academic Research Consortium

ISSN: 1745-6215